Vanguard Global Advisers
MYGN icon

Vanguard Global Advisers’s Myriad Genetics MYGN Stock Holding History

Vanguard Global Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Sell
179,918
-3,450
-2% -$15.7K ﹤0.01% 1731
2026
Q1 		$825K Buy
+183,368
New +$955K ﹤0.01% 1764

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Global Advisers's MYGN Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Myriad Genetics (MYGN) stake by 1.9% in Q2 2026, selling an estimated $15.7K and leaving 179,918 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1731.

Vanguard Global Advisers first reported a position in MYGN in Q1 2026 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Vanguard Global Advisers held 179,918 shares of Myriad Genetics worth $1.03M as of Q2 2026.
  • Vanguard Global Advisers sold 3,450 Myriad Genetics shares in Q2 2026, an estimated $15.7K.
  • Myriad Genetics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1731 holding.
  • Vanguard Global Advisers first reported a position in Myriad Genetics in Q1 2026 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.